Valaciclovir in herpes zoster ophthalmicus: new indication. An empty clinical assessment file.

Abstract	(1) Valaciclovir, a metabolic precursor of aciclovir, improves the bioavailability of the active compound. It is licensed for the prevention of ocular complications of herpes zoster ophthalmicus in immunocompetent subjects. (2) The clinical file on valaciclovir in this indication is very thin. Only two (uninterpretable) trials have been done, both versus aciclovir. Note that oral aciclovir has also been assessed inadequately in this indication. (3) Over 10% of patients treated with valaciclovir in the two trials had nausea or headache.
Authors
Journal	Prescrire international (Prescrire Int) Vol. 8 Issue 41 Pg. 75-6 (Jun 1999) ISSN: 1167-7422 [Print] France
PMID	10558445 (Publication Type: Journal Article)
Chemical References	Antimetabolites Acyclovir
Topics	Acyclovir (administration & dosage, adverse effects, therapeutic use) Antimetabolites Clinical Trials as Topic France Herpes Zoster Ophthalmicus (complications, drug therapy) Humans Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!